GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00954642
A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2016-06-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 107
- Registration Number
- NCT00951665
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT00943670
A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT00932373
A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 218
- Registration Number
- NCT00930163
Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT00928330
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT00927589
A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00909740
A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
- First Posted Date
- 2009-05-01
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1097
- Registration Number
- NCT00891735
A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis
- First Posted Date
- 2009-04-28
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT00888745
- Locations
- 🇭🇺
Investigational Site, Szeged, Hungary
© Copyright 2024. All Rights Reserved by MedPath